The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiation program. Policies on incorporating drugs payable under Medicare Part B or covered under Part D are included in the guidance. It also describes procedures that may apply to drug manufacturers, Part D plan sponsors, Medicare Advantage organizations, pharmacies, mail order services and other Part D drug-dispensing entities, as well as hospitals, physicians and other providers that furnish or administer drugs payable under Part B. CMS is accepting comments on the draft guidance until Sept. 18. 

Headline
The Trump administration announced Aug. 31 agreements with nine additional pharmaceutical manufacturers aimed at lowering prescription drug prices through a…
Headline
The AHA Aug. 31 joined a coalition led by LeadingAge and other national healthcare organizations in submitting comments to the Centers for Medicare &…
Headline
The AHA Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Price…
Headline
The Centers for Medicare & Medicaid Services Aug. 7 released a procedural notice on its new pathway to expedite access to certain Food and Drug…
Headline
The U.S. District Court for the Eastern District of Pennsylvania Aug. 5 granted a motion for the AHA and the Hospital and Healthsystem Association of…
Headline
The Centers for Medicare & Medicaid Services today issued a final rule that would increase Medicare rates by a net 2.3% in fiscal year 2027, compared with…